Clinical response to tocilizumab in patients with severe COVID-19
International Journal of Infectious Diseases — San-Juan R, Fernández-Ruiz M, López-Medrano F, et al. | January 25, 2022
i>NOTE, original article title: Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19
In view of the uncertainty concerning the efficacy of tocilizumab (TCZ) for the treatment of severe COVID-19, researchers herein investigated the profile of TCZ-respondent patients.
Performing a retrospective analysis, researchers identified a cohort of 428 patients that received off-label TCZ after indication of a local Committee.
63.3% of severe COVID-19 treated with tocilizumab showed improvement at 14 days.
Better clinical response was observed in correlation with early administration of tocilizumab.
Researchers suggest a recruitment window of 48 hours from admission in tocilizumab RCTs as advisable.